Stay updated on Immunologic Response to Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Immunologic Response to Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Immunologic Response to Pembrolizumab in Melanoma Clinical Trial page
- Check3 days agoChange DetectedClinicalTrials.gov’s displayed revision version was updated from v3.5.2 to v3.5.3, indicating a site/interface version change rather than an edit to the study’s content.SummaryDifference0.1%

- Check10 days agoChange DetectedAdded Revision: v3.5.2; Deleted Revision: v3.5.0 from the study record history.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check39 days agoChange DetectedRevision 3.5.0 has been added to the record history, and revision 3.4.3 has been removed.SummaryDifference0.1%

- Check46 days agoChange DetectedThe page history shows a new site revision v3.4.3 added and the previous revision v3.4.2 removed.SummaryDifference0.1%

- Check74 days agoChange DetectedA new revision entry (v3.4.2) was added to the history, and an older funding-status notice and revision entry (v3.4.1) were removed as administrative updates.SummaryDifference0.7%

- Check82 days agoChange DetectedA site-wide notice about potential data delays due to a lapse in government funding was added, and the record version was updated from v3.4.0 to v3.4.1.SummaryDifference0.7%

Stay in the know with updates to Immunologic Response to Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunologic Response to Pembrolizumab in Melanoma Clinical Trial page.